I wonder if RAC wanted to put this new collaboration into an ASX announcement but the ASX responded that it didn't qualify as news or if they thought it might be ramping?
It feels like this article does provide significant insight into the progress of the other formulations of Zantrene and that it probably means there has been significant progress.
Ann: Preclinical & Clinical Programs Update, page-25
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.015(0.89%) |
Mkt cap ! $287.1M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.70 | $1.69 | $34.09K | 20.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3312 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.73 | 5300 | 2 |
View Market Depth
| Last trade - 10.29am 16/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |